FDA Advisers Recommend JN.1 Strain for Fall COVID Vaccines
TL;DR Summary
FDA advisers recommend updating fall COVID-19 vaccines to target the JN.1 strain, despite the rise of its offshoots like KP.2, to ensure broader protection against evolving variants. Moderna, Pfizer, and Novavax are preparing JN.1-specific shots, with the CDC to provide further guidance on distribution.
- FDA advisers urge targeting JN.1 strain in recipe for fall's COVID vaccines The Associated Press
- FDA vaccine advisers vote unanimously in favor of updated Covid-19 shot for fall CNN
- COVID shots should target variants with JN.1 lineage in 2024-25 campaign, US FDA advisers say Reuters
- FDA panel supports switch to JN.1 for fall COVID vaccines University of Minnesota Twin Cities
- New Covid Vaccine Endorsed for Fall The New York Times
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
2 min
vs 3 min read
Condensed
91%
482 → 44 words
Want the full story? Read the original article
Read on The Associated Press